12.07.2010 • NewsNovartisAlconNestlé

Novartis Still Seeking To Buy Out Alcon

Swiss drugmaker Novartis is still seeking to buy out the minority shareholders of eyecare group Alcon with a lowball offer, now worth some $9.7 billion.

Here are some key facts about the deal:

• Novartis bought a 25% stake in Alcon for around $10.4 billion or $143 per share in 2008. It exercised an option to buy Nestle's remaining 52% stake in Alcon for $28.1 billion or $180 per share in January.

• Novartis made an offer at the same time to buy out Alcon's minority shareholders for 2.8 Novartis shares per Alcon share. That equates to around $9.7 billion at Friday's prices.

• This offer is equivalent to around $139 per Alcon share, compared with the average of $168 Novartis paid Nestle.

• Novartis says Swiss merger law applies to the deal as Alcon is incorporated in Switzerland, meaning Novartis does not have to pay minorities the same amount.

• Novartis says that under Swiss law it can push through the minorities deal once it takes majority control.

• Swiss mergers require approval of two-thirds of shareholders and a simple board majority.

• An independent committee of Alcon directors (IDC) has repeatedly dismissed Novartis' offer for the minorities as "grossly inadequate."

• Novartis has said it could replace the independent directors once it has secured its majority stake in Alcon.

• A law academic hired by the IDC has advised that approval from the independent directors is needed for a deal to go through.

• The IDC has set up a $50 million trust for litigation between Novartis and Alcon.

• Novartis has said it expects to get regulatory approval for the acquisition of the majority stake in either the late third quarter or fourth quarter.

• Novartis has said that with a 77% stake it could generate annual pre-tax cost synergies of around $200 million within three years.

• Attaining 100% ownership could result in additional annual pre-tax cost synergies of around $100 million within three years of closing the deal.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.